Bevacizumab (Avastin) in Ocular Processes Other Than Choroidal Neovascularization
Authors:
- Levent AkdumanLALevent Akduman
- 1 January 2009
- journal article
- review article
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 17 (2) , 109-117
Abstract
Bevacizumab is a full-length humanized murine monoclonal anti-VEGF (vascular endothelial growth factor) IgG1 antibody that was approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer. The intravenous formulation of bevacizumab was first injected intravitreally in 2005 and has proven to be a relatively safe and extremely effective off-label treatment for neovascular ocular disease and diseases associated with macular edema. This paper is a review of the ophthalmic uses of bevacizumab in processes other than choroidal neovascularization.Keywords
This publication has 39 references indexed in Scilit:
- Topical Bevacizumab Therapy for Corneal NeovascularizationArchives of Ophthalmology (1950), 2007
- Subconjunctival bevacizumab for corneal neovascularizationGraefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Bevacizumab for Neovascular Ocular DiseasesAnnals of Pharmacotherapy, 2007
- Intravitreal Bevacizumab for Filtering SurgeryOphthalmic Research, 2007
- Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)British Journal of Ophthalmology, 2006
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Regression of Iris Neovascularization After Intravitreal Injection of Bevacizumab in Patients With Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 2006
- Intracameral Bevacizumab for Iris RubeosisAmerican Journal of Ophthalmology, 2006
- Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Levels Are Differentially Elevated in Patients with Advanced Retinopathy of PrematurityThe American Journal of Pathology, 2000
- Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucomaOphthalmology, 1998